Gilead Sciences, Inc. (GILD)
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
Here is how Gilead Sciences (GILD) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Gilead Sciences (GILD) closed at $110.67, marking a +2.83% move from the previous day.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Gilead's twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS)'s twice-yearly injectable HIV prevention drug lenacapavir is on track for a solid launch after being officially approved by the US Food and Drug Administration (FDA) on Wednesday, analysts at Jefferies believe. Lenacapavir, marketed as Yeztugo, is the first pre-exposure prophylaxis (PrEP) drug requiring only two treatments per year, offering a significant convenience advantage over daily oral PrEP and cabotegravir, which requires six injections per year.
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
The Food and Drug Administration approved Gilead's twice-yearly antiviral drug for preventing HIV. The company and some experts say it is a milestone that could help bring the world closer to ending the decades-long epidemic caused by the virus.
Should You Buy Gilead Stock At $110?
Despite a recent setback with an FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P 500's modest 2% gain. The company is actively collaborating with authorities to resolve the recent issues and remains focused on improving profitability.
Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline
Initiate Gilead Sciences with Strong Buy/$181 PT, citing disciplined cost base, accelerating pipeline, and robust Q1-25 execution driving margin and EPS outperformance. HIV franchise resilience and upcoming lenacapavir-PrEP launch underpin multi-year growth, with consensus underestimating embedded volume and margin expansion optionality. Disciplined SG&A cuts and high operating leverage enable sustainable margin accretion and above-Street EPS growth, supporting a premium 21x forward P/E multiple.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
